Investor Presentaiton

47 Rigosertib's Current Status and Potential Next Steps Including but not limited to: • Continue enrollment for the Phase 1/2a trial of oral rigosertib + nivolumab in KRAS-mutated, CPI resistant, non-small cell lung cancer • Identification of additional sites and patients for the RDEB-associated SCC trial Initiation of investigator-sponsored study of oral rigosertib + pembrolizumab in patients with CPI resistant melanoma Ongoing preclinical studies in various RASopathies • Preclinical combinations studies with sotorasib and other combinations of interest 0 ONCONOVA THERAPEUTICS

View entire presentation